Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio, Inc. entered into securities purchase agreements for a private investment in public equity (PIPE), selling 1,953,124 ordinary shares and issuing Warrants to purchase 1,953,124 ordinary shares. The securities are priced at $64.00 per ordinary share with an accompanying Warrant, and each Warrant is immediately exercisable at an exercise price of $76.80 per share for two years.
The PIPE is expected to generate gross proceeds of approximately $125 million before fees, with potential additional proceeds of about $150 million if all Warrants are exercised. Closing is expected on or about September 9, 2025, subject to customary conditions. Belite Bio also granted investors registration rights, committing to file a resale registration statement with the SEC within 45 days after closing and to use reasonable best efforts to have it declared effective within specified timeframes.
Form 144 filing for Belite Bio, Inc. (BLTE) reports a proposed sale of 30,000 American Depositary Shares (each representing one ordinary share) through J.P. Morgan Securities LLC on NASDAQ with an aggregate market value of $1,902,600 and an approximate sale date of 08/21/2025. The filer acquired the 30,000 ADS on 03/07/2025 by exercising stock options and paid cash on that date. The filer states there were no securities sold in the past three months attributable to the same person, and the notice includes the standard Rule 144 representation about lack of undisclosed material information.
Belite Bio, Inc. filed a Form 6-K to furnish a press release dated August 11, 2025, in which the company reported its second quarter 2025 financial results and provided a corporate update. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The 6-K also states that this report is deemed incorporated by reference into all of Belite Bio’s effective registration statements under the Securities Act of 1933 from the filing date, unless later superseded. The filing is signed by Chief Executive Officer and Chairman Yu-Hsin Lin.
Belite Bio (Nasdaq: BLTE) filed a 424B5 to raise capital via a direct, best-efforts placement of 230,770 ADSs (1 ADS = 1 ordinary share) at $65.00 each, bundled one-for-one with five-year warrants exercisable at the same price. Gross proceeds total $15.0 million; the placement-agent fee is 6.5% ($0.975 m), leaving $14.0 m before other expenses. Proceeds are earmarked for working capital and general corporate purposes.
Post-offering share count rises to 32.83 m (33.06 m fully diluted). Warrants are immediately exercisable, unlisted, and capped at 9.99% beneficial ownership. Company lock-ups: 30 days (issuer) and 60 days (insiders & ≥5% holder). Closing is expected on 8 Aug 2025; Titan Partners Group acts as exclusive placement agent.
Risks disclosed include continued cash burn, reliance on lead drug Tinlarebant, potential PRC regulatory exposure despite limited China operations, likely PFIC status, dilution (immediate book-value drop of $59.75/ADS) and controlled-company governance exemptions. Last BLTE close (6 Aug 2025) was $67.99, implying a modest 4.4% discount. No change to Nasdaq listing of ADSs; warrants will not be listed.